SinoMab BioScience Limited (HKG:3681)
Hong Kong
· Delayed Price · Currency is HKD 1.930
+0.030 (1.58%)
At close: Mar 10, 2026
SinoMab BioScience Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | - | 2.03 | 1.37 | - | 25.91 | - | Upgrade
|
| Other Revenue | 5.73 | - | - | 4.03 | 0.74 | 12.76 | Upgrade
|
| Revenue | 5.73 | 2.03 | 1.37 | 4.03 | 26.66 | 12.76 | Upgrade
|
| Revenue Growth (YoY) | - | 48.43% | -66.15% | -84.88% | 108.91% | - | Upgrade
|
| Cost of Revenue | - | 1.48 | 0.94 | - | - | - | Upgrade
|
| Gross Profit | 5.73 | 0.54 | 0.42 | 4.03 | 26.66 | 12.76 | Upgrade
|
| Selling, General & Admin | 57.25 | 67.72 | 97.62 | 82.59 | 133.4 | 72.01 | Upgrade
|
| Research & Development | 72.46 | 94.75 | 135.41 | 180.37 | 199.11 | 103.4 | Upgrade
|
| Operating Expenses | 129.7 | 162.47 | 233.02 | 262.96 | 332.51 | 175.41 | Upgrade
|
| Operating Income | -123.98 | -161.93 | -232.6 | -258.93 | -305.86 | -162.65 | Upgrade
|
| Interest Expense | -8.36 | -8.66 | -6.58 | -4.96 | -5.82 | -2.42 | Upgrade
|
| Interest & Investment Income | 5.88 | 5.88 | 6.18 | 9.58 | 16.73 | 17.35 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -5.4 | -4.29 | -0.75 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.58 | -9.47 | -12.81 | -61.89 | 9.88 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.44 | 1.53 | 3.74 | 0.59 | 1.16 | 25.87 | Upgrade
|
| EBT Excluding Unusual Items | -131.6 | -172.65 | -242.08 | -321.01 | -288.19 | -122.6 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.24 | - | - | 39.77 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.08 | 0.08 | - | -1.44 | - | - | Upgrade
|
| Asset Writedown | - | - | - | -1.48 | - | - | Upgrade
|
| Other Unusual Items | -12.58 | -12.58 | -1.03 | - | - | - | Upgrade
|
| Pretax Income | -144.34 | -185.14 | -243.11 | -284.16 | -288.19 | -122.6 | Upgrade
|
| Earnings From Continuing Operations | -144.34 | -185.14 | -243.11 | -284.16 | -288.19 | -122.6 | Upgrade
|
| Net Income | -144.34 | -185.14 | -243.11 | -284.16 | -288.19 | -122.6 | Upgrade
|
| Net Income to Common | -144.34 | -185.14 | -243.11 | -284.16 | -288.19 | -122.6 | Upgrade
|
| Shares Outstanding (Basic) | 1,086 | 1,074 | 1,018 | 992 | 995 | 1,006 | Upgrade
|
| Shares Outstanding (Diluted) | 1,086 | 1,074 | 1,018 | 992 | 995 | 1,006 | Upgrade
|
| Shares Change (YoY) | 3.94% | 5.46% | 2.64% | -0.29% | -1.13% | 20.27% | Upgrade
|
| EPS (Basic) | -0.13 | -0.17 | -0.24 | -0.29 | -0.29 | -0.12 | Upgrade
|
| EPS (Diluted) | -0.13 | -0.17 | -0.24 | -0.29 | -0.29 | -0.12 | Upgrade
|
| Free Cash Flow | -113.18 | -171.97 | -237.19 | -413.29 | -345.3 | -217.29 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.16 | -0.23 | -0.42 | -0.35 | -0.22 | Upgrade
|
| Gross Margin | 100.00% | 26.80% | 30.92% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -2164.76% | -7992.40% | -17040.44% | -6421.80% | -1147.38% | -1274.70% | Upgrade
|
| Profit Margin | -2520.34% | -9138.25% | -17810.33% | -7047.57% | -1081.12% | -960.82% | Upgrade
|
| Free Cash Flow Margin | -1976.25% | -8487.96% | -17376.19% | -10250.22% | -1295.33% | -1702.92% | Upgrade
|
| EBITDA | -111.25 | -147.07 | -213.47 | -244.29 | -296.43 | -158.61 | Upgrade
|
| D&A For EBITDA | 12.72 | 14.86 | 19.13 | 14.63 | 9.43 | 4.04 | Upgrade
|
| EBIT | -123.98 | -161.93 | -232.6 | -258.93 | -305.86 | -162.65 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.